Posts tagged renal cell carcinoma
Stifel downgrades Argos to hold

Stifel downgraded Argos Therapeutics (NASDAQ:ARGS) to “hold” from “buy” and slashed its price target to $1.40 from $10 after an independent data monitoring committee (IDMC) recommended discontinuation of the ADAPT Phase 3 trial of AGS-003 in metastatic renal cell carcinoma (RCC) patients.

Read More
Leerink downgrades Mirna to market perform

Leerink Partners downgraded Mirna Therapeutics (NASDAQ:MIRN) to “market perform” from “outperform” and lowered its price target to $4 from $10, citing added uncertainties around the development path and safety profile of lead product candidate, MRX34. The stock closed at $3.95 on Tuesday.

“While microRNAs represent an intriguing emerging new class of therapeutic targets, recent company updates render us more cautious on the prospects for Mirna shares,” writes analyst Michael Schmidt.

Read More
Stifel upgrades Exelixis to buy

Stifel has upgraded Exelixis (NASDAQ:EXEL) to “buy” from “hold” with a price target of $7. The stock closed at $4.05 on Friday.

Exelixis is developing small molecule therapies for the treatment of cancer and is focusing its development and commercialization efforts primarily on cabozantinib, an internally discovered inhibitor of multiple receptor tyrosine kinases.

Read More